PK Study With Pantoprazole in Obese Children and Adolescents

Exclusion Criteria

• •1. Use of pantoprazole, lansoprazole, omeprazole, esomeprazole or rabeprazole within 48 hours prior to dose of study drug
• •2. Use of fluoxetine, fluvoxamine, ketoconazole, ticlopidine, felbamate, topiramate, valproic acid, phenobarbital, carbamazepine, erythromycin, clarithromycin, grapefruit juice, verapamil, diltiazem, cimetidine, St. John's Wort, rifampin, rifapentine within seven days prior to dose of study drug
• •3. Consumption of food after midnight on the day of the baseline visit
• •4. Symptomatic asthma
• •5. Type I diabetes
• •6. History of adverse reaction to PPI
• •7. Impaired hepatic activity as defined as any of the following: AST ≥150 IU/L, ALT ≥150 IU/L, total bilirubin ≥2.0 mg/dl, or alkaline phosphatase ≥600 IU/L
• •8. Serum creatinine ≥2.0 mg/dL
• •9. For females of childbearing potential, a positive pregnancy test result
• •10. Known infection with hepatitis B, C, or HIV
• •11. Any other condition that, in the opinion of the principal investigator, makes participation unadvised or unsafe.